Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS

Discover why Harrow Inc. (HROW) is a strong buy in 2024—explosive growth from Vevye, rising margins, and a $175 price target.
The Daily Overview on MSN

15 timeless career habits that can save your job

In a volatile job market, the habits you practice every week often matter more than the title on your business card. I focus ...